The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

“90 per cent of patients that have oral cavity cancer are 50 or older,” Dr Slaughter said ... s cancer but genetic testing is ...

Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting ...

These six high-yield dividend stocks are universally loved by investment professionals and they now offer reasonable entry ...

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

The dental industry may see increased demand for hygiene products and dentist visits if the Trump administration follows through on a proposed move to end water fluoridation, CNBC reported Nov. 18.

Nanoform Finland Plc. November 18, 2024. 08:10 a.m. Finnish time / 07:10 a.m. Swedish time. Nanoform Q3 2024 report: Record number of new projects signed. A ...

Revenue growth is back and is expected to accelerate in coming quarters ... the current formulation of these blockbuster medicines - for treatment of prostate cancer - has been an amorphous solid ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today ...

These topline results will be presented on November 19 in a late-breaking oral presentation at the American Association ... subcutaneous injection of a long-acting variant of human fibroblast growth ...

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

Cancer Daily Horoscope Today, November 18, 2024 to know your astrological predictions. Shower love on the partner and keep ...